CABA תחזית צמיחת רווח נקי למניה לשנה הבאה Cabaletta Bio Inc.

Cabaletta Bio, Inc. (CABA) treats autoimmune diseases using CARTA-AID, and the consensus earnings per share (EPS) trend on GURU.Markets visualizes these expectations. 15.70 determines this parameter level. The team's flexibility is supported by external outsourcing of trials, while the production of cell products relies on the capacities of certified centers, eliminating manufacturing downtime.
פילוחים אנליטיים ודוחות נתונים של חברת cabalettabio.com (CABA)

Cabaletta Bio, Inc. (CABA) develops immunological drugs within a protected US legal environment, which is reflected in the trends of the company's EPS forecasts for the coming year. This indicator captures the daily price action of analyst expectations regarding future earnings per share. An upward curve signals improving fundamental prospects, while a decline indicates a reassessment of risks. The stability of this metric confirms the investment security of the asset.